Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
University of Chicago · Fox Chase Cancer Center · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,733
total citations
- FWCI
- 165.63
- Percentile
- 100%
- References
- 30
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Tolerability
- Internal medicine
- Head and neck squamous-cell carcinoma
- Oncology
- Response Evaluation Criteria in Solid Tumors
- Adverse effect
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.